Skip to Content

Orilissa (elagolix) Disease Interactions

There are 3 disease interactions with Orilissa (elagolix):

Major

Elagolix (applies to Orilissa) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures. Because of these increased exposures and risk for bone loss, the use of elagolix is contraindicated in women with severe hepatic impairment (Child-Pugh C). In women with moderate hepatic impairment (Child-Pugh B) elagolix 150 mg is recommended once daily with the duration of treatment limited to 6 months. No dose adjustment is needed for women with mild hepatic impairment (Child-Pugh A).

Major

Elagolix (applies to Orilissa) osteoporosis

Major Potential Hazard, Moderate plausibility.

Elagolix is contraindicated in women with known osteoporosis because of the risk of further bone loss. Elagolix causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.

Moderate

Elagolix (applies to Orilissa) depression/anxiety

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Anxiety/Stress

Suicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials. Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional. Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing elagolix if such events occur.

Orilissa (elagolix) drug interactions

There are 315 drug interactions with Orilissa (elagolix)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.